NCLATcorporateinsolvency
NCLAT Rejects SBI-Linked Insolvency Plea Amid Fraud Claims
The NCLAT ruled to dismiss an insolvency plea against SBI loans, referencing fraud allegations that invalidated the loan documents.
Jul 17, 2026Read more →
Legal News & Insights
AI-curated court updates, legal developments, and practice-area insights for Indian legal professionals.
Corporate Law News
NCLATcorporateinsolvency
NCLAT Dismisses Appeal on Incomplete Resolution Plan
The NCLAT ruled that the appeal against the resolution plan is not maintainable. However, the Ayra Consortium retains the right to argue its intervention application at a later stage.
Jul 17, 2026Read more →
NCLT Mumbaicorporate
NCLT Mumbai Grants Waiver Under Section 244 in Mismanagement Case
NCLT Mumbai has granted a waiver of the maintainability objection under Section 244(1)(b), allowing further proceedings in a petition regarding oppression and mismanagement.
Jul 17, 2026Read more →
Supreme Court of Indiacorporate
Supreme Court Sets Aside SARFAESI Auction Sale for Delayed Payment
The Supreme Court annulled a SARFAESI auction sale, citing non-compliance with payment rules, and provided a one-time opportunity for the legal heir to redeem the property. The ruling emphasizes adherence to auction procedures.
Jul 17, 2026Read more →
Karnataka High Courtcorporate
Karnataka HC Bars Transfer to NCLT in Advanced Liquidation Stage
The Karnataka High Court denied a request to transfer a winding-up petition to the NCLT, ruling that the advanced stage of liquidation requires proceedings to continue in the High Court. This highlights jurisdictional issues in corporate insolvency cases.
Jul 17, 2026Read more →
NCLATcorporate
NCLAT Sets Aside Section 9 Insolvency Admission for Debt Below ₹1 Crore
The NCLAT annulled the admission of a Section 9 insolvency application due to the admitted debt being less than ₹1 crore, ordering a refund of ₹91.98 lakh. This ruling clarifies the threshold for invoking insolvency proceedings under Section 9.
Jul 17, 2026Read more →
N/Acorporate
New SEBI Rules Impede Equity Investments by Employees
New regulations prohibit SEBI employees and their families from making equity investments, marking a significant change for those in regulatory positions. The move aims to prevent conflicts of interest and ensure regulatory integrity.
Jul 14, 2026Read more →
NCLATcorporateinsolvency
NCLAT Limits Remuneration to ₹3 Lakh in International Trenching Case
The NCLAT has upheld the authority of the Committee of Creditors by limiting the insolvency professional's remuneration to ₹3 lakh, reinforcing the framework set by the IBC and IBBI regulations.
Jul 14, 2026Read more →
Reserve Bank of Indiacorporatefinancial
Review of FEMA Circulars by RBI
The RBI has undertaken a comprehensive review of circulars under FEMA to streamline and rationalize the regulatory framework, reflecting the evolving economic landscape.
Jul 14, 2026Read more →
IBBIcorporate
IBBI Suspends Insolvency Professional for Two Years Over Lapses
The IBBI has suspended an Insolvency Professional for two years due to failures in asset valuation and disclosure during the Corporate Insolvency Resolution Process, emphasizing accountability in the field.
Jul 14, 2026Read more →
Calcutta High Courtcorporate
Calcutta HC Returns NCLT-Valuation Plaint for Jurisdiction Bar
The Calcutta High Court dismissed a plaint challenging an NCLT-ordered valuation, stating a lack of territorial jurisdiction and statutory bar. This development emphasizes the importance of jurisdictional considerations in corporate law.
Jul 14, 2026Read more →
N/Acorporateconsumer
Privacy Notices Must Be Clear and Dynamic Under India's DPDP Act
Under India's Data Protection and Digital Privacy Act (DPDP), organizations are required to provide clear, specific, and updated privacy notices. This marks a shift from generic policies to dynamic communication reflecting actual data practices.
Jul 13, 2026Read more →
N/Acorporatehealthcare
CDSCO Comments on Brand Name Extensions in Pharma Industry
The Central Drugs Standard Control Organization seeks feedback on brand name extensions by pharmaceutical companies. This marks a notable regulatory shift in oversight of pharmaceutical branding.
Jul 13, 2026Read more →